… research into novel glutamate-based therapeutic targets with superior antidepressant effects
but … Here, we review ketamine and other potentially novel glutamate-based treatments for …

… antidepressant glutamate-based agents, such as ketamine [24]. mTOR is a ubiquitous and
highly conserved serine/threonine kinase that functions as a protein synthesis regulator by …

… is seen as a great barrier for tracing glutamatergic transmission and, consequently, for
evaluating the MOA of ketamine and other novel potential glutamate-based antidepressants. …

… has stimulated research into glutamate-based mechanisms of action, new NMDAR antagonists
and glutamate-based drugs are yet to display the fast and long-lasting antidepressant …

… In our opinion, novel glutamate-based antidepressants will find application in the treatment
of mood disorders and present an option will be widely used in clinical practice in the future. …

… basis behind this rapid antidepressant response is under active … features associated with
rapid antidepressant response in MDD … to enable glutamate-based precision therapeutics. …

… for antidepressant drugs. Novel potential treatment options have emerged in recent years,
in … Ketamine, the prototypical rapid-acting antidepressant, has received much attention for its …

… new antidepressant gives another long period of unabated symptoms where the health of
the patient remains unprotected. The ability of the glutamate-based antidepressants discussed …

… likely future of glutamate-based therapies and glutamate-based therapeutic manipulations
… developing novel glutamate-based therapeutic targets with better antidepressant effects and …

… that the next generation of antidepressants will consist of … The antidepressant-like effects
of glutamatergic agents have … Here, we summarize the known antidepressant properties of …